Fresenius Kabi USA
Fresenius Kabi USA is the U.S. pharmaceutical and medical technology subsidiary of Germany's Fresenius SE & Co. KGaA, providing injectable drugs, parenteral nutrition, biosimilars, apheresis and IV therapy devices, and cell and gene therapy instruments to hospitals, blood centers, and home care providers across the United States.
- Company typePrivate
- Founded1996
- HeadquartersLake Zurich, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fresenius Kabi USA does
Fresenius Kabi USA, LLC is the U.S. subsidiary of Germany's Fresenius SE & Co. KGaA and operates as a diversified pharmaceutical and medical technology enterprise headquartered in Lake Zurich, Illinois. The company serves U.S. hospitals, acute care clinics, blood and plasma centers, surgical centers, and home/long-term care facilities through four product pillars: Pharma (a leading portfolio of injectable drugs and delivery systems), Biopharma (the BioSpecialized division focused on biopharmaceuticals and biosimilars such as Tyenne/tocilizumab-aazg), Nutrition (parenteral nutrition products for critically and chronically ill patients), and MedTech (apheresis collection systems, plasmapheresis, therapeutic apheresis, blood component manufacturing, autotransfusion devices, IV therapy infusion systems, and cell and gene therapy manufacturing instruments). Its underlying technologies span specialized drug formulation, parenteral nutrition compounding, apheresis and blood processing equipment, and instruments for cell therapy manufacturing, supported by FDA-approved cGMP manufacturing facilities.
Fresenius Kabi USA firmographics
Firmographics- Name
- Fresenius Kabi USA
- Legal name
- Fresenius Kabi USA, LLC
- Website
- https://fresenius-kabi.us
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Fresenius Kabi USA is the U.S. pharmaceutical and medical technology subsidiary of Germany's Fresenius SE & Co. KGaA, providing injectable drugs, parenteral nutrition, biosimilars, apheresis and IV therapy devices, and cell and gene therapy instruments to hospitals, blood centers, and home care providers across the United States.
- Ownership category
- akta.pro rank
Fresenius Kabi USA industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450), Pharmaceutical and Medicine Manufacturing (32541), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industries
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)
Keywords
Where Fresenius Kabi USA is headquartered
LocationHeadquarters
- HQ city
- Lake Zurich
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Fresenius Kabi USA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Products: Sale of injectable drugs including generic and specialty pharmaceuticals used to treat broad spectrum of patients across U.S. healthcare settings. Products include analgesics, antibiotics, and other essential hospital medicines.
- Medical Technology Devices: Sale and service of MedTech products including apheresis collection systems, infusion pumps, blood component manufacturing equipment, and cell and gene therapy instruments.
- Biopharmaceutical Products: BioSpecialized division provides biopharmaceutical medicines through the company's biopharma capabilities, making advanced life-changing treatments more accessible.
- Parenteral Nutrition: PN products used to care for critically and chronically ill patients in hospitals, long-term care facilities, and at home settings.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Fresenius Kabi USA product offering
Product offeringCore offering
Fresenius Kabi USA manufactures and sells injectable pharmaceuticals, parenteral nutrition products, biopharmaceutical medicines, and medical technologies (including infusion systems, apheresis collection devices, blood component manufacturing equipment, cell and gene therapy instruments, and data management solutions) to hospitals, clinics, blood centers, plasma centers, and home care providers across the United States.
Product overview
Fresenius Kabi USA operates as a diversified healthcare company with four core product pillars: Pharma (injectable drugs and delivery systems), Biopharma/BioSpecialized (biopharmaceutical medicines), Nutrition (parenteral nutrition products), and MedTech (medical technologies and devices). The MedTech portfolio is further organized into Blood Collection and Processing (including Apheresis Collection Systems, Plasmapheresis Systems, Therapeutic Apheresis, Component Manufacturing, Manual Blood Collection, Specialty Products, and Autotransfusion), Cell and Gene Therapy Technologies, Data Management Solutions, and IV Therapy. The company also offers Tyenne (tocilizumab-aazg), a tocilizumab biosimilar.
Differentiator
Problem solved
Functional benefit
Brands
- BioSpecialized: Devoted to life-changing treatments, making advanced biopharmaceutical medicines more accessible to more patients.
Products and services
- Pharma (Injectable Drugs and Delivery Systems) Leading portfolio of injectable drugs and delivery systems used to treat a broad spectrum of patients across the U.S., including analgesics, antibiotics, and other essential hospital medicines.
- Biopharma (BioSpecialized) Biopharmaceutical medicines making advanced, life-changing treatments more accessible to more patients in the United States.
- Nutrition (Parenteral Nutrition) Parenteral nutrition (PN) products used to care for critically and chronically ill patients in hospitals, long-term care facilities, and at home.
- IV Therapy (Infusion Systems, IV Solutions, and Accessories) Range of IV therapy offerings including infusion systems, IV solutions, and accessories for hospital and clinical settings.
- Apheresis Collection Systems Full suite of apheresis technologies that help blood center specialists efficiently collect their community's most needed blood products.
- Plasmapheresis Systems Plasmapheresis portfolio focused on the experience of donors, the people at the heart of a plasma center's business.
- Therapeutic Apheresis Platforms Flexible therapeutic apheresis and cell collection platforms for hospitals and blood centers to meet organizational goals.
- Blood Component Manufacturing Equipment Comprehensive blood component manufacturing equipment designed for efficiency and accuracy in blood centers' component manufacturing operations.
- Autotransfusion Devices Autotransfusion devices designed and manufactured to meet the high expectations of perfusionists for surgical blood conservation procedures.
- Cell and Gene Therapy Technologies Instruments and technologies supporting cell therapy labs from process development through full commercialization.
- Data Management Solutions Flexible data management solutions for operational improvements through data-driven insights and integration with computer systems.
- Tyenne (tocilizumab-aazg) Biosimilar FDA-approved tocilizumab biosimilar with COVID-19 indication-specific HCPCS codes for billing and reimbursement.
Companies that use Fresenius Kabi USA
Customer profileSegments3 records
Ideal customer profiles3 records
Fresenius Kabi USA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Fresenius Kabi USA partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- National Home Infusion Association (NHIA)minorFresenius Kabi joined NHIA's Future of Infusion Advisory Council (FIAC), participating in shaping the future of home infusion therapy services and standards.
- Phlow Corp.coreFirst-of-its-kind collaboration to onshore end-to-end domestic manufacture of Epinephrine Injection, USP, an essential medicine at chronic shortage risk in the U.S. Phlow produces the active pharmaceutical ingredient (API) while Fresenius Kabi handles formulation and finished dose production for hospitals and clinics. This creates the nation's first fully domestic supply chain for this drug. Pending FDA and other necessary approvals, the domestically manufactured product could be available to U.S. hospitals in 2027, with the model designed to be scalable to other essential medicines.
Scale indicators1 record
Recent moves4 records
Expansion highlights5 records
Fresenius Kabi USA competitors and assessment
Company assessmentDirect peers
- Haemonetics: Haemonetics directly competes with Fresenius Kabi USA's Blood Collection and Processing portfolio in blood component manufacturing and apheresis technologies for blood centers and plasma operators.
- Baxter International: Baxter directly competes with Fresenius Kabi USA in parenteral nutrition, IV solutions, infusion systems, and hospital injectable pharmaceuticals, addressing the same institutional customer base across the continuum of care.
- ICU Medical: ICU Medical is a direct competitor in IV infusion systems, infusion pumps, and related IV therapy medical devices, serving the same hospital and acute-care customers as Fresenius Kabi USA's IV Therapy and MedTech pillars.
- B. Braun Medical: B. Braun is a direct competitor across injectable pharmaceuticals, IV infusion systems, and parenteral nutrition, serving the same U.S. hospital and clinical customers with overlapping product portfolios.
- Terumo Blood and Cell Technologies: Terumo BCT is a direct peer in apheresis collection systems, plasmapheresis, therapeutic apheresis, and blood component manufacturing equipment sold to blood centers and plasma collection facilities.
- Hikma Pharmaceuticals: Hikma is a direct competitor in generic injectable hospital pharmaceuticals, particularly in analgesia, anesthesia, and anti-infectives, sold into the same institutional supply channels as Fresenius Kabi USA.
Broad incumbents
- Cardinal Health: Cardinal Health is a broad healthcare distribution and medical products incumbent that distributes and competes with portions of Fresenius Kabi USA's MedTech and pharmaceutical portfolio across the U.S. hospital channel.
- Sandoz (Novartis): Sandoz competes directly with Fresenius Kabi USA in generic injectable pharmaceuticals across hospital and institutional channels, but operates as one segment within the broader Novartis-affiliated generics business.
- Pfizer (Injectables / Hospira franchise): Pfizer's sterile injectables portfolio, inherited from Hospira, competes directly with Fresenius Kabi USA's generic injectable franchise across U.S. hospitals, but is one product line within Pfizer's much larger diversified biopharma portfolio.
- Teva Pharmaceutical Industries: Teva's sterile injectable portfolio, including its biosimilar business, competes with Fresenius Kabi USA's generic injectables and Tyenne biosimilar in U.S. hospital channels as part of its broader generics and specialty portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Fresenius Kabi USA social profiles
Digital presenceFresenius Kabi USA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fresenius Kabi USA leadership team
Management profileNumber of profiles
Fresenius Kabi USA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fresenius Kabi USA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fresenius Kabi USA
What does Fresenius Kabi USA do?
Fresenius Kabi USA manufactures and sells injectable pharmaceuticals, parenteral nutrition products, biopharmaceutical medicines, and medical technologies (including infusion systems, apheresis collection devices, blood component manufacturing equipment, cell and gene therapy instruments, and data management solutions) to hospitals, clinics, blood centers, plasma centers, and home care providers across the United States.
Is Fresenius Kabi USA a public or private company?
Fresenius Kabi USA is a private company. It is classified as corporate owned and is currently operating.
When was Fresenius Kabi USA founded?
Fresenius Kabi USA was founded in 1996. It employs 1,001 to 5,000 people.
Where is Fresenius Kabi USA based?
Fresenius Kabi USA is headquartered in Lake Zurich, United States, in the North America region.
How does Fresenius Kabi USA make money?
Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Technology Devices, biopharmaceutical Products and parenteral Nutrition.
Who are Fresenius Kabi USA's main competitors?
Direct peers on record are Haemonetics, Baxter International, ICU Medical, B. Braun Medical, Terumo Blood and Cell Technologies and Hikma Pharmaceuticals. Broad incumbents are Cardinal Health, Sandoz (Novartis), Pfizer (Injectables / Hospira franchise) and Teva Pharmaceutical Industries.
Does Fresenius Kabi USA have an API?
No public API is recorded for Fresenius Kabi USA.
What industry is Fresenius Kabi USA in?
Fresenius Kabi USA's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.